Phase 2 Completed N=201 Treatment

Expanding Use of CGM in Critical Care: Impact on Nurse Work Patterns and Patient Outcomes

Hyperglycemia

Source: ClinicalTrials.gov NCT05571397 ↗

Enrolled (actual)

201

Serious AEs

0.0%

Results posted

Feb 2026

Primary outcomePrimary: Percentage of Time in Target Glycemic Ranges — 76; 65; 69; 61 percentage of time in target ranges — p=<0.001

Summary

The primary objective of this implementation study is to assess the feasibility of real time continuous glucose monitoring (CGM) implementation using a CGM plus (+) point-of-care (POC) protocol among patients on IV insulin or those with hyperglycemia (>250mg/dl) in the critical care hospital environments.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Time in Target Glycemic Ranges	76; 65; 69; 61; 37; 30	<0.001 sig
SECONDARY Percent of Time in Hypoglycemic Ranges	0.41; 0.19; 0.06; 0.08	—

Eligibility Criteria

Inclusion Criteria

adults >18 years old,
admitted to Ohio State University Wexner Medical Center MICU and
have hyperglycemia (glucose >250mg/dl) or are currently on IV insulin.

Exclusion Criteria

Current COVID-19 infection,
Refractory shock (Levophed dose >0.5 mcg/kg/min or equivalent)
Actively being treated for diabetic ketoacidosis (DKA)
Actively being treated for hyperosmolar non-ketoacidosis (HONK)
Pitting edema, anasarca, blue or purple discoloration to left upper extremity
Treated with high dose acetaminophen (>1 gram Q6 hours)
Treated with hydroxyurea
Are pregnant, patients
Using home insulin pump therapy during hospitalization, or
Reside in a corrections institution.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05571397). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.